Volume 21, Issue 4 - Obesity and Type 2 Diabetes

New treatments for type 2 diabetes

Author: Laura Cascales

Abstract

Download the full article

References

1. International Diabetes Federation. Types of diabetes. Available from: http://www.idf.org/types-diabetes
2. World Health Organization. Diabetes fact sheet. 2011; N. 312: Available from: http://www.who.int/mediacentre/factsheets/fs312/en/
3. Centers for Disease Control and Prevention. US National diabetes fact sheet. 2011: Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf
4. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. CMAJ 1922;12(3):141–6.
5. Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes Technol Ther 2011;13(Suppl. 1):S103–8.
6. The Hormone Foundation. Type 2 diabetes and insulin secretagogues. J Clin Endocrinol Metab 2012;97(3):37A–8A.
7. Phielix E, Szendroedi J, Roden M. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol Sci 2011;32(10):607–16.
8. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132(6):2131–57.
9. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91(1):301–7.
10. Gallwitz B. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents. Drugs 2011;71(13):1675–88.
11. Marre M, Penfornis A. GLP-1 receptor agonists today. Diabetes Res Clin Pract 2011;93(3):317–27.
12. Wajcberg E, Tavaria A. Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2009;10(1):135–42.
13. Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 2009;5(1):199–211.
14. Sivertsen J, Rosenmeier J, Holst JJ, Vilsboll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012;9(4):209–22.
15. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2011;34(S27):S27–S33.
16. Novo Nordisk Inc. Liraglutide US prescribing information. 2010: Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022341s004lbl.pdf
17. Garber AJ. Novel GLP-1 receptor agonists for diabetes. Expert Opin Investig Drugs 2012;21(1):45–57.
18. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 2005;108(4):277–92.
19. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res 2012;9(2):109–16.
20. Verspohl EJ. Novel pharmacological approaches to the treatment of type 2 diabetes. Pharmacol Rev 2012;64(2):188–237.
21. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71(11):1441–67.
22. Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther 2012;14(4):350–64.
23. Ashcroft FM, Rorsman P. Diabetes mellitus and the beta cell: the last ten years. Cell 2012;148(6):1160–71.
24. World Health Organization. Obesity and overweight fact sheet. 2012; N. 311 Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html
25. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444(7121):840–6.
26. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012;18(3):363–74.
27. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393–403.
28. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54(10):2506–14.